Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25849170 | 0.87 | PKM (0.49) | PKMCASP1ALDH1A1KMT2AATM | |
| SCHEMBL25849159 | 0.84 | CYP2C19 (0.46) | CASP1ALDH1A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL25849172 | 0.80 | PKM (0.55) | PKMCASP1ALDH1A1ATMMAPK1 | |
| SCHEMBL15043610 | 0.76 | MAPK1 (0.61) | PKMALDH1A1ATMMAPK1L3MBTL1 | |
| SCHEMBL2590178 | 0.76 | MAPK1 (0.61) | PKMALDH1A1ATMMAPK1L3MBTL1 | |
| SCHEMBL25849153 | 0.76 | GSK3A (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL1190731 | 0.73 | ALDH1A1 (0.61) | PKMALDH1A1KMT2AATMMAPK1 | |
| SCHEMBL1190730 | 0.73 | ALDH1A1 (0.61) | PKMALDH1A1KMT2AATMMAPK1 | |
| SCHEMBL25849171 | 0.72 | ALDH1A1 (0.44) | ALDH1A1KMT2AMAPK1L3MBTL1CYP2C19 | |
| SCHEMBL17232606 | 0.72 | MAPK1 (0.47) | PKMALDH1A1KMT2AATMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203474-A1 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2023-06-29 | — | — | US | disclosed |
| US-20230203474-A1 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203474-A1 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | SNRPA, NSUN2, POLRMT | PKM 1412/4885CASP1 3973/4885ALDH1A1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.